Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Express Scripts
Boehringer Ingelheim
Johnson and Johnson
Harvard Business School
Colorcon
McKesson

Last Updated: January 23, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Indoximod

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the development status for investigational drug Indoximod?

Indoximod is an investigational drug.

There have been 14 clinical trials for Indoximod. The most recent clinical trial was a Phase 1 trial, which was initiated on October 1st 2017.

The most common disease conditions in clinical trials are Glioma, Glioblastoma, and Brain Neoplasms. The leading clinical trial sponsors are NewLink Genetics Corporation, National Cancer Institute (NCI), and Theodore S. Johnson.

There are fifty-seven US patents protecting this investigational drug and four hundred and forty-one international patents.

Recent Clinical Trials for Indoximod
TitleSponsorPhase
Pediatric Trial of Indoximod With Chemotherapy and Radiation for Relapsed Brain Tumors or Newly Diagnosed DIPGEmory UniversityPhase 2
Pediatric Trial of Indoximod With Chemotherapy and Radiation for Relapsed Brain Tumors or Newly Diagnosed DIPGTheodore S. JohnsonPhase 2
A 2-part, Phase 1, Randomized Study in Health Men to: 1) Evaluate the Pharmacokinetics and Safety of Different Doses Indoximod HCL (Salt) Tablets and; 2) Compare the Proportion of 2 Different Formulations of Indoximod That Enters the Circulation andNewLink Genetics CorporationEarly Phase 1

See all Indoximod clinical trials

Clinical Trial Summary for Indoximod

Top disease conditions for Indoximod
Top clinical trial sponsors for Indoximod

See all Indoximod clinical trials

US Patents for Indoximod

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Indoximod   Start Trial Monomethylvaline compounds having phenylalanine side-chain modification at the C-terminus Seattle Genetics, Inc. (Bothell, WA)   Start Trial
Indoximod   Start Trial Antibodies to ICOS Jounce Therapeutics, Inc. (Cambridge, MA)   Start Trial
Indoximod   Start Trial Tank-binding kinase inhibitor compounds Gilead Sciences, Inc. (Foster City, CA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
AstraZeneca
Colorcon
Harvard Business School
McKinsey
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.